Growth Hormone and Athletic Performance
GH Peptides and Performance
+3.9% sprint capacity
The only consistent performance benefit of GH administration in healthy adults, from a meta-analysis of placebo-controlled trials.
Hermansen et al., Growth Hormone & IGF Research, 2017
Hermansen et al., Growth Hormone & IGF Research, 2017
View as imageGrowth hormone is one of the most misunderstood substances in sports. Athletes have used it for decades based on the assumption that more GH means more muscle, more power, and better recovery. The research tells a different story. A 2008 systematic review in the Annals of Internal Medicine (Liu et al.) analyzed 27 studies encompassing 440 participants and found that GH increased lean body mass by an average of 2.1 kg but did not improve strength, power, or aerobic capacity. The IGF-1 and muscle growth connection is real, but more GH does not automatically translate into better athletic performance.
Key Takeaways
- GH administration increases lean body mass by approximately 2.1 kg in controlled trials, but this does not translate to improved strength or power output (Liu et al., Annals of Internal Medicine, 2008)
- The only consistent performance benefit is a 3.9% improvement in anaerobic sprint capacity, with effects stronger in men (+5.5% alone, +8.3% with testosterone)
- GH does not improve VO2 max, muscle strength, or aerobic exercise capacity in healthy young adults
- GH secretagogue MK-677 reversed diet-induced nitrogen wasting and increased IGF-1 by 40% in a crossover RCT of 8 healthy volunteers (Murphy et al., 1998)
- WADA-banned GH secretagogues (GHRP-2, GHRP-6, ipamorelin) have been found in seized doping materials with glycine modifications to evade detection (Gajda et al., 2019)
- Hexarelin and JMV2894 prevented cisplatin-induced muscle calcium dysregulation and preserved grip strength in a rat cachexia model (Conte et al., 2017)
What GH Actually Does to the Body
Growth hormone acts primarily through two pathways: direct lipolytic effects on fat tissue and indirect anabolic effects mediated by insulin-like growth factor 1 (IGF-1), produced mainly in the liver. GH stimulates protein synthesis, promotes lipolysis, and enhances collagen synthesis in tendons and cartilage.
When exogenous GH is administered to healthy adults, the most consistent physiological change is a shift in body composition: fat mass decreases and lean mass increases. But "lean mass" includes water, connective tissue, and organ mass, not just contractile muscle protein. This distinction matters because athletes care about functional muscle, not total lean mass.
GH also promotes fluid retention, which contributes to apparent lean mass gains. Soft tissue edema and joint swelling are among the most reported side effects in GH supplementation trials. The 2.1 kg average lean mass increase observed across controlled trials likely reflects a combination of actual protein accretion, water retention, and connective tissue growth. Growth hormone-treated participants more frequently experienced soft tissue edema and fatigue than placebo groups across the 27 studies analyzed by Liu et al. (2008).
The Evidence on Strength and Power
The research is unambiguous on this point: GH does not improve muscle strength in healthy adults.
Hermansen et al. (2017) conducted a meta-analysis of placebo-controlled trials specifically examining GH's effect on athletic performance in healthy young adults. GH produced significant changes in body composition (increased lean mass, decreased fat mass) but did not increase muscle strength or aerobic exercise capacity (Growth Hormone & IGF Research, 2017). The disconnect between increased lean mass and unchanged strength suggests the mass gains are not functional contractile tissue.
Meinhardt et al. (2010) conducted the largest randomized trial specifically designed to test GH in recreational athletes. In 96 subjects who received GH (2 mg/day in men, 1.5 mg/day in women) or placebo for 8 weeks, GH increased lean body mass and decreased fat mass but had no effect on muscle strength or VO2 max (Annals of Internal Medicine, 2010). The one exception was sprint capacity: GH increased anaerobic sprint capacity in men by approximately 5.5%, and combined GH plus testosterone increased it by 8.3%.
This pattern repeats across multiple trials: body composition changes reliably, but functional performance does not. For those interested in whether GH peptides actually improve strength, the distinction between GH itself and GH-releasing peptides adds another layer of complexity.
Sprint Capacity: The One Consistent Finding
Sprint performance is the sole athletic domain where GH shows a repeatable effect. The Hermansen 2017 meta-analysis found a marginally significant 3.9% improvement in anaerobic sprint capacity when pooling male and female participants (p=0.05). In men alone, the effect was 5.5% with GH monotherapy and 8.3% when GH was combined with testosterone. The effect was not significant in women.
The mechanism behind this sprint-specific effect is unclear. It may relate to GH's effects on fast-twitch muscle fiber metabolism, its influence on connective tissue stiffness (which affects power transfer), or changes in substrate utilization during high-intensity anaerobic effort. Whatever the mechanism, the effect is modest: a 4-6% sprint improvement is detectable in laboratory testing but may not meaningfully alter competitive outcomes in sports where margins are measured in hundredths of seconds.
This sprint benefit has not been demonstrated with GH secretagogues like GHRP-2 or MK-677 in controlled human trials. All performance data comes from studies administering recombinant human GH directly, not from indirect GH stimulation via peptides.
GH Secretagogues and Body Composition
While the key athletic performance trials used recombinant GH, research on GH secretagogues provides relevant context about GH-mediated body composition changes and whether peptide-based GH stimulation produces similar effects.
MK-677 and Nitrogen Balance
Murphy et al. (1998) conducted a double-blind, placebo-controlled crossover study in 8 healthy volunteers placed on caloric restriction. MK-677 at 25 mg daily reversed diet-induced negative nitrogen balance, shifting it from -1.48 g/day (placebo) to +0.31 g/day (MK-677, p<0.01). IGF-1 concentrations increased from 186 to 264 ng/mL, a roughly 40% rise. Peak GH response after the first dose reached 55.9 mcg/L compared to approximately 9 mcg/L with placebo.[1]
This demonstrates that oral GH secretagogues can achieve anti-catabolic effects comparable to GH injections, at least in the short term. Whether this nitrogen-sparing effect translates to functional performance benefits in trained athletes has not been tested. The compound is reviewed in detail at MK-677 (ibutamoren).
MK-677 in Elderly Adults
Chapman et al. (1996) showed daily oral MK-677 (25 mg) increased 24-hour GH concentrations by 97% and restored IGF-1 levels to the young adult range in 32 healthy subjects aged 64-81 over 4 weeks.[2] The treatment enhanced pulsatile GH release without affecting cortisol. However, fasting glucose increased significantly from 5.4 to 6.8 mmol/L, highlighting a metabolic trade-off that is directly relevant to athletes concerned about insulin sensitivity. This insulin resistance concern is explored further in MK-677 and blood sugar.
Tesamorelin and Fat Reduction
Badran et al. (2026) published a meta-analysis of randomized controlled trials showing tesamorelin, a GHRH analogue, reduced visceral adipose tissue by 27.71 cm2 (p<0.001), trunk fat by 1.18 kg (p<0.001), and increased lean body mass by 1.42 kg (p<0.001) in HIV-associated lipodystrophy.[7] This mirrors the body composition pattern seen with exogenous GH: reduced fat, increased lean mass, but no strength testing was performed. More on this compound at tesamorelin.
GH Secretagogues and Muscle Protection
Beyond body composition, GH secretagogues show promise in protecting skeletal muscle from disease-induced wasting, though this is distinct from performance enhancement.
Conte et al. (2017) found that hexarelin and JMV2894 prevented cisplatin-induced dysregulation of skeletal muscle calcium homeostasis in rats. Cisplatin-treated muscle showed an 18% reduction in muscle weight, two-fold increase in resting intracellular calcium, and 50% reduction in calcium transient amplitude. Both GH secretagogues normalized calcium handling and preserved grip strength, with effects mediated through both GHS-R1a-dependent and independent mechanisms.[4]
Aagaard et al. (2009) demonstrated that ipamorelin reduced urea synthesis by 20% and improved nitrogen balance in steroid-treated rats, though GH injection was 33% more effective at the doses used.[6]
These findings suggest GH secretagogues have direct protective effects on skeletal muscle beyond simple GH elevation. However, preventing muscle wasting in disease states is fundamentally different from enhancing performance in healthy athletes. The gap between muscle protection and performance enhancement remains wide.
Why Athletes Use GH Despite Weak Evidence
If the evidence for GH-enhanced performance is weak, why do athletes use it? Several factors explain the gap between research and practice.
Detection difficulty. GH was nearly undetectable in standard anti-doping tests for decades. The World Anti-Doping Agency banned GH in 1989 but reliable testing methods did not emerge until much later. Gajda et al. (2019) identified glycine-modified analogs of GHRP-2, GHRP-6, ipamorelin, and modified GRF 1-29 in seized doping materials, where the N-terminal glycine addition was specifically designed to evade detection methods.[5]
Stacking. Athletes rarely use GH alone. They combine it with anabolic steroids, insulin, and other compounds. The sprint capacity data showing an 8.3% improvement with GH plus testosterone (versus 5.5% with GH alone) suggests synergistic effects in combination that are absent in monotherapy trials. Real-world "stacking" protocols have never been tested in controlled research for obvious ethical reasons.
Recovery. GH's effects on collagen synthesis and connective tissue repair are well-documented in clinical contexts. Athletes may use GH for faster recovery from training and injuries rather than direct performance enhancement. This application is plausible given GH's known effects on connective tissue, but has not been specifically validated in athlete recovery trials.
Placebo effect and confirmation bias. Athletes who feel leaner and perceive more muscle definition from GH's body composition effects may attribute performance improvements to GH regardless of objective changes in strength or speed. The visible body composition changes (less fat, more apparent muscularity) reinforce the belief that GH is "working," even when force production has not changed.
The broader picture of why athletes are drawn to GH peptides explores these motivations in more detail.
Exercise and GH Secretagogue Interactions
Wideman et al. (2000) investigated how exercise modulates the synergistic GH response to combined L-arginine and GHRP-2 in 18 healthy subjects (9 men, 9 women). At rest, combining L-arginine and GHRP-2 produced synergistic (supra-additive) GH release. Exercise potentiated the individual stimulatory effects of both compounds but blunted their synergistic interaction. This blunting occurred in men but not women, revealing a gender-specific interaction between exercise and GH peptide responses.[3]
The researchers concluded exercise likely induces both GHRH and somatostatin release simultaneously, which competes with the exogenous GHRP-2 signal. L-arginine may facilitate exercise-induced GH release by limiting somatostatin, while GHRP-2 enhances it by opposing central somatostatin effects. The practical implication: taking GH secretagogues around exercise may not produce the additive GH boost that users expect, particularly in men.
The comparison of natural GH release from exercise versus exogenous peptides addresses this timing question directly.
The Lean Mass Paradox
The central paradox of GH and athletic performance is this: GH reliably increases lean body mass, and lean body mass generally correlates with strength and power in healthy populations. Yet GH-induced lean mass gains do not improve strength or power.
The most likely explanation is that GH-induced lean mass is qualitatively different from training-induced lean mass. Resistance exercise builds contractile myofibrillar protein within muscle fibers, the tissue that actually generates force. GH appears to increase non-contractile components: water, connective tissue, organ tissue, and extracellular matrix. The lean mass gained from GH may look similar on a DEXA scan but functions differently when generating force against resistance or propelling the body forward.
This is supported by the observation that GH's most consistent effect is on body composition (fat loss, lean mass gain) rather than functional outcomes. Tesamorelin's 1.42 kg lean mass increase in HIV lipodystrophy patients was not accompanied by strength testing.[7] MK-677's nitrogen-sparing effects were measured biochemically, not functionally.[1]
Until a controlled trial demonstrates that GH-induced lean mass gains translate into measurable strength or power increases, the lean mass paradox remains the defining feature of the GH-performance relationship.
For understanding how the GH-IGF-1 axis relates to actual muscle growth, the GHRP-2 vs GHRP-6 comparison and GHRH pathway provide additional mechanistic context.
The Bottom Line
Growth hormone increases lean body mass by approximately 2.1 kg and reduces fat mass in controlled trials, but does not improve muscle strength, power output, or aerobic capacity in healthy adults. The sole consistent performance benefit is a modest 3.9-5.5% improvement in anaerobic sprint capacity, with stronger effects when combined with testosterone. GH secretagogues like MK-677 produce comparable body composition effects through oral administration, but no controlled human trial has demonstrated athletic performance enhancement from GH-releasing peptides. Athletes continue to use GH and GH peptides based on perceived recovery benefits, detection difficulty, and combination protocols, rather than on evidence of direct performance gains.